Projet VIRION (Horizon 2020, appel à projets 2014)
Action : Doctoral Networks - Industrial Doctorates
Panel : Life Sciences
Statut du projet : CLOSED

The Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION) is focused on the execution of an internationally competitive cancer research project focused on the development of a novel therapeutic regime by combining immune therapy with oncolytic virotherapy and RNA interference techniques. Recent clinical successes have shown the immune system to be a powerful ally in the fight against cancer. While surgery, chemotherapy and radiation therapy remain the first lines of treatment for most tumors, immunotherapy regimens have had astonishing clinical successes. Furthermore, recent studies have shown that pre-existing lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers and might improve cancer therapies targeting immune checkpoints. A recent development in the immunotherapy field is adoptive cell therapy (ACT). In ACT lymphocytes from cancer patients are expanded ex vivo into more favorable numbers, they can be modified genetically or stimulated to relieve immune suppression and infused back into the patient. In clinical trials, ACT has resulted in anti tumor responses. However, immune suppression in the tumor microenvironment limits the efficacy of immunotherapy and remains a major hurdle. We aim to potentiate the antitumor immune reaction in the tumor microenvironment through the combination of immune therapy and oncolytic virotherapy. Oncolytic viruses are developed to specifically target and destroy tumor cells. In pre-clinical models, oncolytic adenoviruses have proven a powerful tool in the elimination of tumors, not only by their direct lytic effects but also by their triggering of a subsequent tumor inflammation and enhanced lymphocytic infiltration. VIRION will address how these immune responses can be further enhanced by addition of immune modulating factors and/or siRNA targeting tumor genes that play an immune suppressive role in the tumor micro environment.

Mots clés : immune therapy, adaptive cell therapy, tumor infiltrating lymphocytes, anti tumour immune response, oncolytic virotherapy, rna interference

Participants :
- Amsterdam University Medical Centers (Pays-Bas) — Coordinator, beneficiary, Recherche, subvention : 510748.56 €
- Hyphen projects bv (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Vrije Universiteit Amsterdam (Pays-Bas) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Quintess consultancy bv (Pays-Bas) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Adiutide pharmaceuticals gmbh (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Netherlands society of gene and cell therapy (Pays-Bas) — Partner, organization partner, Autres, subvention : 0.0 €
- Diamond biopharm limited (Royaume-Uni) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Tilt biotherapeutics oy (Finlande) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 538290.72 €
- Orca therapeutics bv (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 255374.28 €